Ambroxol Shows Potential as a Parkinson Disease Drug


Of the 176 adverse events found in a trial targeting ambroxol as a Parkinson disease drug, only 3 were deemed related to the treatment.

Stephen Mullin, PhD

Stephen Mullin, PhD

New data points to ambroxol as a potential treatment to target the glucocerebrosidase pathway in patients with Parkinson disease.

A team, led by Stephen Mullin, PhD, Department of Clinical and Movement Neurosciences, University College London Institute of Neurology, discovered ambroxol therapy could be used as a neuroprotective compound to treat patients with Parkinson disease both with and without glucocerebrosidase (GBA1) gene mutations.

The investigators conducted an open-label clinical trial involving 17 patients with Parkinson disease and found ambroxol crossed the blood-brain barrier and bound to the β-glucocerebrosidase (GCase) enzyme, increasing β-glucocerebrosidase enzyme protein levels and cerebrospinal fluid (CSF) α-synuclein levels in patients with or without glucocerebrosidase gene mutations.

They sought the primary outcomes of the detection of ambroxol in the cerebrospinal fluid GCase activity at 186 days.

The trial took place between January 2017 and April 2018 at the Leonard Wolfson Experimental Neuroscience Centre, a clinical research facility that is part of the University College London Queen Square Institute of Neurology.

Participants in the study were recruited from established databases at the Royal Free London Hospital and National Hospital for Neurology and Neurosurgery in London.

The team observed a 156-ng/mL increase in the level of ambroxol in cerebrospinal fluid (lower 95% confidence limit, 129 ng/mL; P&thinsp; <.001) between 0-186 days, while the CSF GCase activity decreased by 19% (.059 nmol/mL per hour; 95% CI, —.115 to –.002; P =&thinsp;.04).

An increase in treatment to 50 pg/mL (13%) in the CSF α-synuclein concentration (95% CI, 14-87; P = .01) and an increase of 88 ng/mol (35%) in the CSF GCase protein levels (95% CI, 40-137; P&thinsp;= .002) was also observed.

Overall, the new therapy was well tolerated with no serious adverse events.

A total of 176 adverse events occurred, but 121 were deemed unrelated, 32 unlikely to be related, 15 possibly related, 5 probably related, and only 3 were definitely related to treatment. Those adverse events included nauseam vomiting, a burning sensation after swallowing the medicine, and a transitory skin condition on the chest, back, and arms.

For patients with and without GBA1 mutations, the mean scores on part 3 of the Movement Disorders Society Unified Parkinson Disease Rating Scale decreased by 6.8 (7.1) points (95% CI, —10.4 to –3.1; P&thinsp;=&thinsp;.001).

“The study results suggest that ambroxol therapy was safe and well tolerated; CSF penetration and target engagement of ambroxol were achieved, and CSF α-synuclein levels were increased,” the authors wrote. “Placebo-controlled clinical trials are needed to examine whether ambroxol therapy is associated with changes in the natural progression of [Parkinson disease].”

The mutations of the glucocerebrosidase gene can cause the autosomal recessive lysosomal storage disorder or Gaucher disease. Both in vitro and in vivo studies have found ambroxol increases β-glucocerebrosidase enzyme activity and reduce α-synuclein levels.

These mutations are a genetic risk factor for Parkinson disease, exhibiting penetrance of 10-30% and are present in 5-15% of Caucasian patients with Parkinson disease, 25% of Ashkenazi Jewish patients with Parkinson disease, and only 1% of individuals without the disease.

Ambroxol therapy has been used as a cough linctus since the 1970s, with principal adverse effects being gastrointestinal disturbance and a small risk of anaphylaxis. A high-throughput compound evaluation indicated that ambroxol delivered a pH-dependent increase in GCase activity.

The investigators suggest larger placebo-controlled studies are warranted.

The study, “Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations,” was published online in JAMA Neurology.

Related Videos
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Mikkael Sekeres, MD:
Lynn Malec, MD: FVIII Therapy Improves Levels in Pediatric Patients with Hemophilia A
Lynn Malec, MD:
Guy Young, MD: More Advancement for Subcutaneous Hemophilia Treatments
Guy Young, MD
Margaret Ragni, MD: Liver Abnormalities in Hemophilia A Gene Therapy Require Close Monitoring
John Harsh, PhD: Exploring Once-Nightly Sodium Oxybate Therapy for Narcolepsy
© 2024 MJH Life Sciences

All rights reserved.